1. "2018"
Formats
  1. Journal Article (3011)
  2. Meeting Abstract (1948)
  3. Book Section (206)
  4. Conference Paper (38)
  5. Book Whole (11)
  6. Editorial (4)
  7. Review (4)
  8. Miscellaneous (2)
  9. Correspondence (1)
Groups
  1. Department of Medicine (2296)
  2. Solid Tumor Oncology Division (1378)
  3. GSK Faculty (1136)
  4. Sloan Kettering Institute Postdocs (1044)
  5. Surgery (870)
  6. Center for Hematologic Malignancies (863)

More Groups

People
  1. Sergio Giralt (87)
  2. Matthew Hellmann (78)
  3. Jedd Wolchok (74)
  4. Marc Ladanyi (74)
  5. Robert Motzer (71)
  6. Nancy Lee (64)

More People

Years
  1. 2018 (5225)
Publications
  1. Journal of Clinical Oncology (562)
  2. Blood (249)
  3. Cancer Research (183)
  4. Annals of Oncology (140)
  5. International Journal of Radiation Oncology, Biology, Physics (137)
  6. Modern Pathology (127)

More Publications

Publishers
  1. Elsevier Inc. (691)
  2. American Society of Clinical Oncology (605)
  3. Springer (410)
  4. American Association for Cancer Research (299)
  5. Oxford University Press (291)
  6. American Society of Hematology (273)

More Publishers

Results (5225)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The ECHELON-2 trial: Results of a randomized, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas
    Meeting Abstract

    Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Illidge, T. M.; Fanale, M. A.; Advani, R. H.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase 1 study of ADCT-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma
    Meeting Abstract

    Hamadani, M.; Collins, G. P.; Samaniego, F.; Spira, A. I.; Davies, A.; Radford, J.; Caimi, P.; Menne, T.; Boni, J.; Cruz, H.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: Results from the NCRI AML trials
    Meeting Abstract

    Hills, R. K.; Gale, R.; Linch, D. C.; Huntly, B. J. P.; Papaemmanuil, E.; Vyas, P.; Burnett, A. K.; Russell, N. H.
    Blood (2018)

    Fulltext@MSK | Save
  • The novel SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Feldman, T. A.; Hess, B. T.; Khodadoust, M. S.; Kim, Y. H.; Munoz, J.; Patel, M. R.; Phillips, T. J.; Smith, S. D.; Smith, S. M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia
    Meeting Abstract

    Goldberg, A. D.; Talati, C.; Desai, P.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Sallman, D. A.; Lancet, J. E.; Roboz, G. J.; Sweet, K. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Leukemia risk gene ARID5B is a crucial regulator of B-cell development
    Meeting Abstract

    Goodings-Harris, C.; Zhang, H.; Zhao, X.; Xu, H.; Abdel-Wahab, O. I.; McKinney-Freeman, S.; Yang, J. J.
    Blood (2018)

    Fulltext@MSK | Save
  • Characterization of novel subtypes in B progenitor acute lymphoblastic leukemia
    Meeting Abstract

    Gu, Z.; Churchman, M. L.; Roberts, K. G.; Moore, I.; Zhou, X.; Nakitandwe, J.; Hagiwara, K.; Pelletier, S.; Gingras, S.; Berns, H.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Alisertib (MLN8237), an oral selective inhibitor of aurora kinase A, has clinical activity and restores GATA1 expression in patients with myelofibrosis
    Meeting Abstract

    Gangat, N.; Stein, B. L.; Marinaccio, C.; Swords, R.; Watts, J. M.; Gurbuxani, S.; Frankfurt, O.; Altman, J. K.; Wen, J. Q.; Farnoud, N.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Addition of crenolanib to induction chemotherapy overcomes the poor prognostic impact of co-occurring driver mutations in patients with newly diagnosed FLT3-mutated AML
    Meeting Abstract

    Goldberg, A. D.; Collins, R. H.; Stone, R. M.; Walter, R. B.; Karanes, C.; Vigil, C. E.; Wang, E. S.; Tallman, M. S.
    Blood (2018)

    Fulltext@MSK | Save
  • Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naive acute lymphoblastic leukemia
    Meeting Abstract

    Gaulin, C.; Chan, A.; Geyer, M. B.; Park, J. H.; Mantha, S.; Tallman, M. S.
    Blood (2018)

    Fulltext@MSK | Save